NINE MASTS CAPITAL Ltd bought a new stake in shares of AstraZeneca Plc (NYSE:AZN – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 8,400 shares of the company’s stock, valued at approximately $1,356,000.
A number of other large investors have also recently made changes to their positions in the stock. Intech Investment Management LLC grew its stake in AstraZeneca by 13.8% in the 3rd quarter. Intech Investment Management LLC now owns 134,037 shares of the company’s stock worth $21,866,000 after acquiring an additional 16,212 shares in the last quarter. Silver Oak Securities Incorporated purchased a new position in shares of AstraZeneca during the third quarter worth approximately $180,000. Harbour Investments Inc. bought a new stake in shares of AstraZeneca during the third quarter valued at approximately $1,139,000. FDx Advisors Inc. bought a new stake in shares of AstraZeneca during the third quarter valued at approximately $368,000. Finally, Optas LLC raised its stake in shares of AstraZeneca by 1.5% during the third quarter. Optas LLC now owns 6,959 shares of the company’s stock valued at $1,124,000 after acquiring an additional 100 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
AZN has been the subject of a number of research reports. CICC Research began coverage on AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target for the company. Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Royal Bank Of Canada began coverage on AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating for the company. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Finally, Zacks Research upgraded AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average target price of $206.67.
Check Out Our Latest Research Report on AZN
AstraZeneca Price Performance
NYSE AZN opened at $184.66 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.79 and a current ratio of 1.01. The firm’s 50 day moving average price is $168.82 and its 200-day moving average price is $180.20. AstraZeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71. The company has a market cap of $286.40 billion, a PE ratio of 26.12, a P/E/G ratio of 1.43 and a beta of 0.24.
AstraZeneca (NYSE:AZN – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. The company had revenue of $16.21 billion during the quarter, compared to analyst estimates of $16 billion. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. AstraZeneca’s revenue was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.38 earnings per share. Sell-side analysts forecast that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.
AstraZeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Stories
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
